Patients with a genetic sensitivity to warfarin may have higher rates of bleeding during the first several months of treatment and could benefit from therapy with an alternate anticoagulant medication, reports a new study in The Lancet.
Your search for Warfarin returned 5 results
Treatment visits for use of anticoagulants are on an upward trend and driven largely by the popularity of new direct oral anticoagulants, which tripled in use from 2013-2014.
Daiichi Sankyo announced that Savaysa (edoxaban) tablets are now available to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF), and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association have been published in the American Journal of Respiratory and Critical Care Medicine.
Clinicians should carefully consider the risks and benefits of triple therapy, as new research reports that in older patients with acute myocardial infarction (MI) and atrial fibrillation (AF), triple therapy did not reduce the risk of major cardiovascular events but was associated with a greater risk of bleeding.